STOCK TITAN

Perspective Therapeutics director buys 6,289 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. (CATX) director Robert F. Williamson III reported a direct purchase of 6,289 common shares on November 12, 2026, at a weighted-average price of $0.8386 per share. The RFW3 Revocable Trust was identified as the indirect owner of another 18,609 shares purchased that day at $0.8400 per share. After the transactions, Williamson held 115,271 shares directly and 28,473 shares through the trust.

Insider Williamson Robert F III
Role Director
Bought 24,898 shs ($21K)
Increase in Position 20.9%
Type Security Shares Price Value
Purchase Common Stock 18,609 $0.84 $16K
Purchase Common Stock F1 6,289 $0.8386 $5K
Holdings After Transaction: Common Stock — 28,473 shares (Indirect, RFW3 Revocable Trust); Common Stock — 115,271 shares (Direct)
Holdings Before and After: Common Stock, 9,864 to 28,473 shares (Indirect, RFW3 Revocable Trust); Common Stock, 108,982 to 115,271 shares (Direct)
Other Insiders: 4 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (1)
  1. F1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8380 to $0.8400, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.
Direct common shares purchased 6,289 shares Robert F. Williamson III, November 12, 2026
Direct purchase weighted-average price $0.8386 per share Multiple transactions; prices ranged from $0.8380 to $0.8400, inclusive
Direct shares held after transaction 115,271 shares Robert F. Williamson III
Trust common shares purchased 18,609 shares RFW3 Revocable Trust, November 12, 2026
Trust purchase price $0.8400 per share RFW3 Revocable Trust
Trust shares held after transaction 28,473 shares RFW3 Revocable Trust
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CATX shares did Robert F. Williamson III and the RFW3 Revocable Trust buy?

Robert F. Williamson III, a director, bought 6,289 common shares directly, and the RFW3 Revocable Trust bought 18,609 shares indirectly, both on November 12, 2026. The direct purchase price was a weighted average of $0.8386 per share; the trust purchase price was $0.8400 per share.

What was the price range for Williamson's direct CATX purchase?

The direct purchase involved multiple transactions at prices ranging from $0.8380 to $0.8400 per share, inclusive. The reported weighted-average price was $0.8386 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williamson Robert F III

(Last)(First)(Middle)
C/O PERSPECTIVE THERAPEUTICS, INC.
2401 ELLIOTT AVENUE, SUITE 320

(Street)
SEATTLE WASHINGTON 98121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026P18,609A$0.8428,473IRFW3 Revocable Trust
Common Stock11/12/2026P6,289A$0.8386(1)115,271D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8380 to $0.8400, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.
/s/ Robert F. Williamson, III by Chris Nenno, as Attorney-in-Fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading